- The IPO price was set at € 66/share, based on an offer of ~12.2 million shares.
- The proceeds amount to ~€808m, of which ~€100m will flow into the company. The remainder will go to Näder Holding.
- The free float will be around 19%, while the Näder family will largely retain control.
- Ottobock intends to use the proceeds for investments, acquisitions and growth.
- Sales and adjusted EBITDA increased significantly in the first half of 2025: sales of € 666 → 760 million, EBITDA € 132 → 175 million.
- Prior to the IPO, institutional investors secured commitments to participate (e.g. Capital Group).
- Ottobock is admitted to the Prime Standard.
- The IPO is seen as a signal that the German capital market is once again becoming more attractive for medical technology.
Opportunities and risks:
Access to capital for expansion & innovation
Signal effect for further IPOs in the medical/technology segment
- Large outflows to the holding company (not to the operating business)
- Price volatility possible in early weeks
- Outlook and implementation of investment plans must be convincing
